Today’s pharmaphorum podcast addresses the subject of speed – the velocity at which biopharma is bringing new therapies and medicines to market faster.
Next-generation technology is enabling drug discovery at an entirely new scale, accelerating the process, transforming therapies and advancing precision medicine, and resulting in better pa
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh